Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation inhibition for sepsis.

Nigel S Key1, E Wesley Ely

  • 1Department of Medicine, University of Minnesota Medical School, 480 Mayo Building, 420 Delaware St SE, Minneapolis, MN 55455, USA. keyxx001@umn.edu

Current Opinion in Hematology
|August 13, 2002
PubMed
Summary

Activated protein C (APC) shows promise in sepsis treatment, offering benefits beyond anticoagulation. Further research into other coagulation inhibitors like antithrombin and tissue factor pathway inhibitor (TFPI) is ongoing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2024
Same author

Data-derived subtypes of delirium during critical illness.

EBioMedicine·2024
Same author

Comparison of SAT and SBT Conduct During the ABC Trial and PILOT Trial.

Journal of intensive care medicine·2023
Same author

Discussions on VT4COVID.

The Lancet. Respiratory medicine·2023
Same author

Holistic care in healthy aging: Caring for the wholly and holy human.

Aging cell·2023
Same author

Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19.

Influenza and other respiratory viruses·2023

Area of Science:

  • Critical care medicine
  • Hematology
  • Pharmacology

Background:

  • Sepsis treatment has seen numerous failed clinical trials for adjunctive therapies.
  • Activated protein C (APC) demonstrated positive outcomes in a recent phase III trial, renewing optimism for targeted biotherapies.

Purpose of the Study:

  • To evaluate the therapeutic potential of APC in sepsis.
  • To explore the mechanisms of APC's protective effects beyond anticoagulation.
  • To contextualize APC's efficacy within the broader landscape of coagulation system inhibitors.

Main Methods:

  • Review of preclinical and clinical data for APC in sepsis.
  • Analysis of a recent phase III clinical trial for APC.
  • Consideration of data from trials involving antithrombin and tissue factor pathway inhibitor (TFPI).

Related Experiment Videos

Main Results:

  • APC demonstrated a protective effect against mortality in sepsis.
  • Evidence suggests APC's benefits stem from anti-inflammatory and profibrinolytic activities, not solely antithrombotic effects.
  • A trial of antithrombin failed to show protective effects, highlighting the need for further investigation.

Conclusions:

  • APC offers a potential targeted biotherapy for sepsis, with multifaceted mechanisms of action.
  • The efficacy of APC suggests that other antithrombotic agents may also hold therapeutic value in sepsis.
  • Future studies will likely investigate other coagulation inhibitors and combination therapies for sepsis management.